February 8, 2017

Division of Dockets Management
Food and Drug Administration
Room 1061, HFA-305
5630 Fishers Lane
Rockville, MD 20852

PETITION TO STAY AND FOR RECONSIDERATION

On behalf of the Medical Information Working Group (MIWG), the Pharmaceutical Research and Manufacturers of America (PhRMA), and the Biotechnology Innovation Organization (BIO), we respectfully submit the following Petition to Stay and for Reconsideration (Petition).

I. Decision Involved

This Petition challenges the final rule entitled Clarification of When Products Made or Derived From Tobacco Are Regulated As Drugs, Devices, or Combination Products; Amendments to Regulations Regarding “Intended Uses” (Final Rule), which was published in the Federal Register on January 9, 2017.1 In particular, this Petition challenges the amendments that the Final Rule would make to Food and Drug Administration (FDA) regulations defining the legal concept of “intended use.”2

II. Actions Requested

A. Pursuant to 21 C.F.R. § 10.35(b), the MIWG respectfully requests that the Commissioner of Food and Drugs (Commissioner) indefinitely stay the Final Rule.

B. Pursuant to 21 C.F.R. § 10.33(b), the MIWG respectfully requests that the Commissioner reconsider the Final Rule and direct FDA staff to promulgate final definitions of intended use that are consistent with the proposed definitions set out in the notice of proposed rulemaking dated September 25, 2015.3

---

2 See 21 C.F.R. §§ 201.128, 801.4.
III. Statement of Grounds

A. Background

This Petition arises out of FDA’s unexpected decision in January 2017 to revise the definitions of “intended use” for drugs and medical devices in 21 C.F.R. §§ 201.128 and 801.4 to include a new “totality of the evidence” standard. FDA’s revisions were not communicated to the public prior to the Final Rule published on January 9, 2017, which deprived stakeholders of fair notice and an opportunity to be heard in violation of the Administrative Procedure Act (APA). Moreover, if allowed to take effect, the revisions would run contrary to the settled interpretation of both the statutory definitions that turn on “intended use” in the Federal Food, Drug, and Cosmetic Act (FDCA) and the requirement that drug and device labeling include “adequate directions for use.”

1. Intended Use Under The FDCA

The “intended use” of a product is a core operational principle around which the FDCA is organized. The concept of an intended use has its origins in the Pure Food and Drugs Act (1906 Act), which had defined the term “drug” to include both those drugs listed in the official compendia and any other “substance or mixture of substances intended to be used for the cure, mitigation, or prevention of disease.” Through this definition Congress ensured that the labeling and purity requirements of the 1906 Act would not be “confine[d] . . . to any definition of ‘drug’ found in dictionaries or pharmacopoeias.” Congress was specifically concerned to ensure that the law apply to “proprietary” medications that were not listed in any compendia but were marketed subject to claims of therapeutic value.

From the outset, the “intended use” prong of the drug definition related to the manufacturer’s claims for its products. Mundane articles were deemed drugs when marketed with therapeutic claims, and when manufacturers sought to claim the benefit of drug status for

---

4 See, e.g., 21 U.S.C. § 321(g)(1)(B)-(D) (defining drugs); id. § 321(h)(2)-(3) (defining devices); id. § 321(i)(1)-(2) (defining cosmetics); id. § 321(s) (defining food additives); id. § 321(w) (defining animal feed); id. § 321(ff)(1) (defining dietary supplements); id. § 321(rr) (defining tobacco products).

5 Ch. 3915, § 6, 34 Stat. 768, 769 (June 30, 1906) (emphasis added).

6 Bradley v. United States, 264 F. 79, 81 (5th Cir. 1920).

7 See Hearing on H.R. 3109 before the S. Comm. on Manufactures, 57th Cong., 4 (Jan. 20, 1903); see generally Hearings on S. 198 Before the S. Comm. on Manufactures, 58th Cong. (Jan. 6, 1904).

8 See, e.g., Bradley, 264 F. at 80 (water deemed to be a drug when marketed with therapeutic claims); Goodwin v. United States, 2 F.2d 200, 200 (6th Cir. 1924) (same).
their products, they were often unsuccessful unless they could show that their products had been marketed with therapeutic claims.

When the FDCA was enacted in 1938, its sponsors made clear that intended use would turn on representations by the manufacturer. Committee reports in 1934 and 1935 likewise explained that

The manufacturer of the article, through his representations in connection with its sale, can determine the use to which the article is to be put. For example, the manufacturer of a laxative which is a medicated candy or chewing gum can bring his product within the definition of drug and escape that of food by representing the article fairly and unequivocally as a drug product.

As another example, “soaps sold only for ordinary toilet or household use . . . [would] not be subject to the definition of drug, [but] soaps for which claims concerning disease are made or which are sold as pharmacopoeial articles will come within the definition of drug and will thus be subject to regulation.”

Courts have treated this legislative history as authoritative. For instance, in United States v. 46 Cartons . . . Fairfax Cigarettes, the district court relied on it to hold that cigarettes marketed with therapeutic claims were properly categorized as drugs. In United States v.

9 At the time, drugs were frequently subject to less stringent regulation than other classes of products. See, e.g., Peter Barton Hutt, Government Regulation of Health Claims in Food Labeling and Advertising 41 Food and Drug L.J. 3, 5 n.8 (1986) (“Because food misbranding could be proved merely by showing a ‘misleading’ statement, it was more difficult for FDA to win a drug misbranding case than a food misbranding case.”).

10 See, e.g., Jury Instructions, United States v. Four Boxes of Mulford’s Wintergreens (N.D.N.Y. 1914) (“Now, gentleman, wintergreen they tell you is a drug. A stick of wintergreen candy which you buy for your child you would hardly call a drug. . . . However, gentlemen, . . . if that was the purpose in its manufacture and sale, even though a large amount of sugar and but a trifle of this essence or oil it, why, then, of course, it would at once . . . take its place in the category of drugs”), reprinted in Otis H. Gates, Decisions of Courts in Cases under the Federal Food and Drugs Act, 593 (1934); see also Savage v. Scovell, 171 F. 566, 567 (E.D. Ky. 1908) (“Plaintiff is in no position to complain of his article being treated as what he calls it”); Commonwealth v. Marzynski, 21 N.E. 228, 229 (Mass. 1889) “[T]here was no evidence in the present case that the cigars which the defendant sold were used, or were intended to be used, as a medicine.”) (emphasis added).

11 See, e.g., Hearings on S. 2800 before the Comm. on Commerce, 73d Cong., 517-18 (Feb. 27 to Mar. 3, 1934) (colloquy between Senator Royal S. Copeland and Walter G. Campbell) (explaining that a chiropractor’s table would not be subject to the act unless the manufacturer “were to ship that table into interstate commerce, and say that that table would cure various ills”).


2. FDA’s Intended Use Definition

As described above, section 502(f)(1) of the FDCA states that a drug or device is misbranded unless its labeling “bears adequate directions for use.” Although Congress amended section 503(b)(2) of the FDCA in 1951 to provide that 502(f)(1) does not apply to prescription drugs, FDA promulgated a regulation in 1952 that purported to exempt prescription drugs from section 502(f)(1) only if, among other things, the prescription drug’s labeling contains “adequate information” regarding any “use for which [the drug] is intended.” The 1952 regulation also created the first ever regulatory definition of intended use. According to FDA:

The words “intended uses” or words of similar import . . . refer to the objective intent of the persons legally responsible for the labeling of

16 NNFA v. FDA, 504 F.2d 761, 789 & n.35 (2d. Cir. 1974).
18 Id. at 239.
23 See id. § 353(b)(2).
24 21 C.F.R. § 201.100(c)(1).
drugs and devices. The intent is determined by such persons’ expressions or may be shown by the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives. It may be shown by the circumstances that the article is, with the knowledge of such persons or their representatives, offered and used for a purpose for which it is neither labeled nor advertised. The intended uses of an article may change after it has been introduced into interstate commerce by its manufacturer. If, for example, a packer, distributor, or seller intends an article for different uses than those intended by the person from whom he received the drug, such packer, distributor, or seller is required to supply adequate labeling in accordance with the new intended uses. But if a manufacturer knows, or has knowledge of facts that would give him notice, that a drug or device introduced into interstate commerce by him is to be used for conditions, purposes, or uses other than the ones for which he offers it, he is required to provide adequate labeling for such a drug which accords with such other uses to which the article is to be put.25

The above definition of intended use became codified at 21 C.F.R. § 201.128 (for drugs) and at 21 C.F.R. § 801.4 (for medical devices) where it remained in place without substantive revision until the events at issue in this Petition.26

FDA’s intended use definition has always been problematic, particularly the last sentence regarding a manufacturer’s knowledge of actual uses and the corresponding obligation to “provide adequate labeling.” Manufacturers specifically objected in 1952 to the possibility that misbranding liability could be based on a known, but not manufacturer-recommended, use. They objected, as well, to any obligation to provide labeling regarding such a use.27

Courts also have questioned FDA’s intended use definition. In 1998, FDA published a rule purporting to require manufacturers of approved drugs “to provide adequate labeling” regarding the use of their products in children, even if pediatric use was neither claimed nor

---

25 Id. § 1.106(o) (1955 ed.) (emphasis added).
27 See, e.g., Letter from John L. Hammer, Vice President, Smith, Kline & French Labs. to Hearing Clerk, Federal Security Agency (Mar. 4, 1952) (objecting that, under the new intended use regulation, if a manufacturer’s “market research department learns that 20% of the purchasers use the preparation as a sedative . . . [and] he inserts in his label directions for use as a sedative . . . he is forced into the position of recommending his product for a use of which he heartily disapproves and for which his drug may be largely ineffective”).
recommended. 28 Citing 21 C.F.R. § 201.128, FDA contended that an approved drug’s intended uses include “the actual uses of the drug of which the manufacturer has, or should have, notice, even if those uses are not promoted by the manufacturer.” 29 That reasoning was rejected by the court in Association of American Physicians and Surgeons, Inc. v. FDA, which ruled that FDA “may only regulate claimed uses of drugs, not all foreseeable or actual uses.” 30 The court found the agency’s reliance on 21 C.F.R. § 201.128 particularly unavailing because “‘no order or regulation issued by an administrative agency can confer on it any greater authority than it has under the statute.’” 31

More recently, medical product manufacturers have challenged FDA’s intended use definition as an unconstitutional restraint on protected speech regarding unapproved uses of approved medical products. A lawsuit brought by Allergan, Inc. in 2009 alleged that FDA’s intended use regulations had chilled speech regarding methods to minimize the risks and improve the quality of patient care related to a particular off-label use. 32 Similarly, a lawsuit brought by Par Pharmaceuticals, Inc. in 2011 alleged that the government had chilled speech by purporting to find a new, unapproved intended use based on the identity of the audience hearing the plaintiff’s speech related to an approved indication. 33 FDA settled both cases before the district court could rule, but made representations in each case limiting how it would interpret and apply 21 C.F.R. § 201.128. In the Allergan case, FDA stated that “not all speech or actions by a manufacturer regarding an unapproved use is [sic] taken by FDA to be evidence of intended use.” 34 FDA further stated that, contrary to the last sentence of 21 C.F.R. §§ 201.128 and 801.4, the agency “usually” does not rely on a manufacturer’s knowledge to infer an intended use. 35 Similarly, during oral argument in Caronia, the court asked whether a crime is committed if a person “hasn’t promoted but he sent [a drug] out knowing and perhaps intending that it be used for something other than an on-label use.” The government counsel replied: “I believe not, your Honor, I don’t think that would be a crime.” 36

---

29 Id. at 66658.
31 Id. at 215 n.17 (quoting Office of Consumers’ Counsel v. FERC, 655 F.2d 1132, 1149 n. 32 (D.C. Cir. 1980)).
35 Id. at 22.
36 Tr. of Oral Arg. At 10, United States v. Caronia, No. 09-5006 (2d Cir. Dec. 2, 2010).
3. The Rulemaking At Issue

FDA’s intended use definition also has been the subject of at least two citizen petitions. First, a petition submitted in 2001 requested that FDA strike the last sentence of 21 C.F.R. § 201.128 (regarding a manufacturer’s knowledge or notice of actual use) because it was inconsistent with “the general regulatory scheme for review and approval of products based on claims made by the sponsor.” FDA has never addressed that petition on its merits.

Second, in September 2013, the MIWG submitted a petition urging the agency to conduct a comprehensive review of its regulations in view of the limitations imposed by the Fifth and First Amendments. Among other things, the MIWG specifically requested that FDA strike the last sentence of 21 C.F.R. §§ 201.128 and 801.4 concerning knowledge. In June 2014, FDA granted the MIWG’s citizen petition and committed to “a comprehensive review of the regulatory regime governing communications about medical products.” In December 2014, FDA reiterated that taking action on the issues raised by the MIWG’s petition were among FDA’s “highest priorities” for 2015.

a. FDA’s Proposed Rule Would Have Acknowledged Key Limits on the Scope of “Intended Use.”

In September 2015, FDA published a notice of proposed rulemaking that appeared to grant the relief requested by both the MIWG and the 2001 petition. FDA explained that changes to 21 C.F.R. §§ 201.128 and 801.4 were needed “to reflect how the agency currently applies them to drugs and devices.” Citing its own briefing from the Allergan case, FDA stated that it will no longer “regard a firm as intending an unapproved new use for an approved or cleared medical product based solely on that firm’s knowledge that such product was being prescribed or used by doctors for such use.” Accordingly, FDA proposed the following alterations to the intended use definitions:

The words intended uses or words of similar import … refer to the objective intent of the persons legally responsible for the labeling of drugs. The intent is determined by such persons’ expressions or may be shown by the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims,

---

41 80 Fed. Reg. at 57756.
42 Id. at 57761.
advertising matter, or oral or written statements by such persons or their representatives. It may be shown, by the circumstances in which the article is, with the knowledge of such persons or their representatives, offered and used for a purpose for which it is neither labeled nor advertised. The intended uses of an article may change after it has been introduced into interstate commerce by its manufacturer. If, for example, a packer, distributor, or seller intends an article for different uses than those intended by the person from whom he received the drug, such packer, distributor, or seller is required to supply adequate labeling in accordance with the new intended uses. But if a manufacturer knows, or has knowledge of facts that would give him notice, that a drug introduced into interstate commerce by him is to be used for conditions, purposes, or uses other than the ones for which he offers it, he is required to provide adequate labeling for such a drug which accords with such other uses to which the article is to be put.43

FDA asserted that, in light of the positions taken in the Allergan case, the deletion of the last sentence in the intended use definition “would not reflect a change in FDA’s approach regarding evidence of intended use for drugs and devices.”44 Notably, the preamble to the proposed rule included no discussion of any alternative approaches, options, or proposals regarding the intended use definition.

FDA originally provided stakeholders 60 days to submit written comments on the proposed rule, through November 24, 2015.45 In response to a request for an extension, FDA held the docket open for comments through December 30, 2015.46 FDA received nearly 2,000 comments on the proposal, most of which did not directly address the revisions to 21 C.F.R. §§ 201.128 and 801.4. The comments that did discuss those revisions generally lauded FDA’s proposal, although some proposed additional changes to make the intended use definition more consistent with the language of the statute and/or constitutional requirements.47 For its part, the

43 See id. at 57764-65.
44 Id. at 57761.
45 Id. at 57756.
MIWG understood that FDA’s proposal to strike the last sentence of sections 201.128 and 801.4 was part of FDA’s effort to take action on the MIWG’s 2013 petition, which had been granted in June 2014.48

After proposing to strike the last sentence of the old intended use definition, FDA finally took administrative action on the 2001 citizen petition. As discussed, that petition had requested precisely the same relief as was proposed by FDA in the September 2015 notice.49 Just before the deadline for comments on that proposal, FDA sent a letter to the successor of the law firm that had filed the 2001 citizen petition. FDA’s letter stated that “the petition ha[d] been inactive for many years” and suggested that the petition had become moot in light of the proposed rule.50 Two months later, after the comment period had closed, FDA unilaterally deemed the 2001 petition to have been withdrawn.51

b. The Final Rule Unexpectedly Expanded the Understanding of Intended Use.

On January 9, 2017, however, FDA dramatically shifted gears. Rather than delete the final sentence of the intended use definition, the agency replaced it with an entirely new sentence that created an open-ended “totality of the evidence” standard:

But if And if the totality of the evidence establishes that a manufacturer knows, or has knowledge of facts that would give him notice objectively intends that a drug introduced into interstate commerce by him is to be used for conditions, purposes, or uses other than the ones for which he offers it is approved (if any), he is required to provide, in accordance with section 502(f) of the Federal Food, Drug, and Cosmetic Act, or, as applicable, duly promulgated regulations exempting the drug from the requirements of section 502(f)(1), to provide for such drug adequate labeling for such a drug which that accords with such other intended uses to which the article is to be put.52

The Final Rule did not claim that this “totality of the evidence” standard had been mentioned as part of the proposed rulemaking. Nor did the Final Rule claim that the new “totality” standard

48 See MIWG, Comments to Docket No. FDA-2015-N-2002, 1 (Nov. 24, 2015). The MIWG also explained that, contrary to FDA’s position, ongoing government investigations continued to assert that intended use could be shown through knowledge of actual use. See id. at 2.
50 Letter from Nan Kim, FDA to Terry S. Coleman, Ropes & Gray (Dec. 22, 2015).
51 Memorandum from Office of Regulatory Policy, FDA to Division of Dockets Management, FDA re: Docket No. FDA-2001-P-0521 (Feb. 1, 2016).
52 82 Fed. Reg. at 2217.
had been proposed by any of the numerous comments submitted. Instead, FDA claimed that certain, unidentified comments had “misunderstood FDA’s proposal” to delete the last sentence of sections 201.128 and 801.4. FDA claimed that it had sought in the proposed rule to clarify that knowledge of an actual use did not “automatically trigger obligations for the manufacturer to provide labeling,” but had not meant to suggest that knowledge would be “eliminate[d] . . . altogether as a source of evidence of intended use.” FDA therefore concluded that its goals would “be better achieved by amending the last sentence of each regulation, rather than deleting them.”

B. Argument

The Final Rule published on January 9, 2017 should be stayed indefinitely and reconsidered for two independent reasons. First, the Final Rule was promulgated in violation of the APA because it failed to give parties subject to potentially significant and far-reaching liability fair notice or a meaningful opportunity to comment. Second, while the agency claims that the Final Rule was merely a clarification of law, it in fact adopted a new “totality of the evidence” standard for finding an intended use that is not found in the FDCA or the case law addressing the intended use question.


The notice-and-comment provisions of the APA “are designed (1) to ensure that agency regulations are tested via exposure to diverse public comment, (2) to ensure fairness to affected parties, and (3) to give affected parties an opportunity to develop evidence in the record to support their objections to the rule and thereby enhance the quality of judicial review.” To fulfill these goals, an agency must “make its views known to the public in a concrete and focused form so as to make criticism or formulation of alternatives possible.” The agency must “describe the range of alternatives being considered with reasonable specificity,” and “set out [the agency’s] thinking,” so that parties can respond with an “adversarial critique of the agency.” Thus, although a final rule need not be identical to the proposed rule, the two “may

53 Id. at 2205.
54 Id. at 2206.
55 Id.
57 HBO, Inc. v. FCC, 567 F.2d 9, 36 (D.C. Cir. 1977).
59 HBO, 567 F.2d at 36, 55.
60 Small Refiner, 705 F.2d at 546.
differ only insofar as the latter is a ‘logical outgrowth’ of the former.”61 If the agency wishes to pursue an alternative that is not a logical outgrowth of the original proposed rule, the agency must provide a supplemental notice of proposed rulemaking and provide an additional opportunity for comment.62

As to the intended use definitions in 21 C.F.R. §§ 201.128 and 801.4, the Final Rule was a stark reversal of the proposed rule and, therefore, violated the APA’s notice-and-comment provisions. While the proposed rule would have helped to address substantial concerns regarding FDA’s intended use definitions, the Final Rule instead exacerbates those concerns. As discussed, regulated entities have long argued that it is inappropriate to impose liability based solely on knowledge of actual use. Industry representatives have requested revisions to FDA’s intended use regulations in comments dating back to 1952 and also filed formal citizen petitions requesting that FDA reconsider its approach. The 2015 proposed rule appeared to be responsive to those concerns by striking the final sentence of the intended use regulations entirely.

Deleting the last sentence from 21 C.F.R. §§ 201.128 and 801.4 would have altered FDA’s intended use definitions in two important respects. First, it would have deleted the only command found in either regulation—namely, the command that manufacturers “provide adequate labeling” for known, but not recommended, uses.

Second, it would have resulted in a streamlined definition focusing on certain types of claims attributable to the manufacturer. Specifically, the proposed rule would have left three operative sentences providing that

The intent is determined by such persons’ expressions or may be shown by the circumstances surrounding the distribution of the article. This objective intent may, for example, be shown by labeling claims, advertising matter, or oral or written statements by such persons or their representatives. It may be shown, for example, by circumstances in which the article is, with the knowledge of such persons or their representatives, offered and used for a purpose for which it is neither labeled nor advertised.63

These sentences would have limited the definition of intended use to manufacturers’ “expressions” (most notably labeling and advertising) and sales and marketing activities (how the product is both “offered and used”). Thus, the definition in the proposed rule would have turned solely on the manufacturer’s promotional statements.


63 80 Fed. Reg. at 57764.
The Final Rule significantly altered course, changing the definition of intended use by introducing a new, and overly broad, “totality of the evidence” standard that is not found in the FDCA and allows FDA to consider any evidence, including knowledge. Furthermore, the Final Rule restores to the regulations the command that manufacturers provide “adequate labeling.” These changes were not hinted at in FDA’s proposed rule, which promised only a modest clarification to the agency’s intended use regulations. The agency therefore failed to give regulated parties fair notice of a fundamental change to the regulatory scheme for drugs and devices.64 The revisions contained within the Final Rule thus violate the fundamental principle that agencies may not “use the rulemaking process to pull a surprise switcheroo.”65

The comments submitted on the 2015 proposed rule further demonstrate that the Final Rule violates the logical outgrowth doctrine. Although close to 2,000 comments were received on the proposed rule, the overwhelming majority pertained to the tobacco regulations covered in the proposal; only a relative few even addressed the intended use definitions applicable to drugs and medical devices. If FDA had provided medical product manufacturers with notice that it was considering retaining the command in the last sentence of 21 C.F.R. §§ 201.128 and 801.4 and expanding the definition of intended use to include a new totality of the evidence standard, then FDA “would doubtless have triggered an avalanche of comments, in contrast to the mere [handful of] pages that . . . actually” addressed intended use.66

For instance, if given an opportunity, stakeholders surely would have challenged FDA’s decision to use a “totality” approach as an FDCA linchpin. As the Supreme Court has observed, a “totality” standard is “not a test at all but an invitation to make an ad hoc judgment.”67 The Court also previously invalidated a “totality” approach in the patent context on the ground that it was “unnecessarily vague” and failed to provide inventors with “a definite standard” to guide their decisions.68 These concerns about overbreadth and vagueness take on special weight where, as here, FDA is purporting to define the scope of its own jurisdiction.69 Indeed, the ad

---

64 That industry lacked notice of the change is clear from both these circumstances and from FDA’s claim that stakeholder comments reflected confusion about the import of the proposed revision. 82 Fed. Reg. at 2205-2206 (referring to comments that “misunderstood FDA’s proposal”).

65 Envtl. Integrity Project, 425 F.3d at 996.

66 Allina Health Servs. v. Sebelius, 746 F.3d 1102, 1108 (D.C. Cir. 2014).

67 City of Arlington v. FCC, 133 S. Ct. 1863, 1874 (2013); see also ABC, Inc. v. Aereo, Inc., 134 S. Ct. 2498, 2517 (2014) (Scalia, J., dissenting) (“th’ol’ totality-of-the-circumstances test . . . is not a test at all but merely assertion of an intent to perform test-free, ad hoc, case-by-case evaluation”).

68 Pfaff v. Wells Elecs., 525 U.S. 55, 65-66 & n.11 (1988); see also United States v. Rivera-Rodriguez, 318 F.3d 268, 276 (1st Cir. 2003) (explaining that the Sentencing Commission had amended the guideline for a departure based on aberrant behavior to overrule the “totality of circumstances” approach adopted by the First Circuit and other courts on the ground that it was “overly broad and vague”).

69 FDA’s statements in the final rule’s accompanying preamble—which are binding statements of official agency policy according to the agency’s own regulations, 21 C.F.R. § 10.85(k)—demonstrate the breadth of the new “totality” standard. The preamble states that FDA will define intended use based on “evidence of a manufacturer’s
hoc approach endorsed in the Final Rule would allow qui tam relators and prosecutors to predicate claims or charges against a manufacturer on the entirely legitimate activity of accurately forecasting demand for products (which typically includes a mix of approved and unapproved uses) and then scaling production to meet that demand. Neither the statute nor the decades of case law construing it justify such a sweeping approach to the intended use inquiry.\(^{70}\) Moreover, as discussed below, exposing companies to potential liability based on an ad hoc totality standard raises significant constitutional questions.

The APA requires that industry be provided notice and a meaningful opportunity to comment before the agency promulgates a regulation with such profound consequences. The proposed rule did not provide such notice. The proper recourse to remedy this absence of notice is for the agency to stay the Final Rule and promulgate a revised rule consistent with the notice of proposed rulemaking published in September 2015.

2. **“Totality Of The Evidence” Is A New And Unjustified Legal Standard.**

In the preamble to the Final Rule, FDA argues that the new “totality of the evidence” standard has “solid support” in the law because courts allegedly have allowed FDA to consider “any relevant source” of evidence, including “a variety of direct and circumstantial evidence” such as the “circumstances surrounding the manufacture and distribution of a medical product.”\(^{71}\) FDA further asserts that the “totality” standard is inconsequential and does not reflect a change in the law or in the agency’s practices.\(^{72}\) These arguments lack merit. There is no support in existing law for the totality standard, and it would represent a substantial change with significant constitutional and public health ramifications.

---


\(^{70}\) \textit{Cf. Nat’l Nutritional Foods Ass’n (NNFA) v. Mathews}, 557 F.2d 325, 334-35 (2d Cir. 1977) (“The determination that an article is properly regulated as a drug [or device] is not left to the Commissioner’s unbridled discretion to act to protect the public health but must be in accordance with the statutory definition[s].”); \textit{Health Prods. Co. v. Hayes}, 574 F. Supp. 1498, 1507 (S.D.N.Y. 1983) (“[A] court’s responsibility to construe the [FDCA] in accord with its protective purposes does not confer a license to ignore congressional judgments reflected in the classification scheme.”), \textit{aff’d on other grounds}, 744 F.2d 912 (2d Cir. 1984).

\(^{71}\) \textit{See} 82 Fed. Reg. at 2206; \textit{see also id.} at 2195-96, 2199, 2202, 2208.

\(^{72}\) \textit{See, e.g., id.} at 2204.
a. The totality standard has no basis in existing law.

FDA’s claim that the totality standard is a mere clarification that tracks existing law is incorrect. The FDCA does not contain the phrase “totality of the evidence,” and the courts have not endorsed that approach to intended use. Moreover, the first and only FDA document to assert that intended use should be assessed according to a “totality” standard appears to be a final guidance published in November 2013 regarding in vitro diagnostic (IVD) products. The draft IVD guidance published in 2011 was highly controversial, and it drew objections from both industry and Congress regarding FDA’s approach to intended use. Tellingly, however, the 2011 draft IVD guidance did not include the “totality” standard, which was seemingly created out of thin air for the final guidance in 2013. In short, the Final Rule is attempting to codify a highly controversial standard that is inconsistent with the statute and case law and has never been subjected to public scrutiny.

In addition, the “totality” standard set out in the Final Rule is directly contrary to the case law constraining FDA’s ability to rely on “circumstantial” evidence. In NNFA v. FDA, the Second Circuit indicated that a vitamin product could be found a drug under the statutory definition even without label claims of a product’s therapeutic value, but such a finding would have to be based on “something more than demonstrated uselessness” as a non-therapeutic product “for most people.” A few years later, the Second Circuit indicated that FDA might establish a “drug” intended use by showing that the vitamins had been “used almost exclusively for therapeutic purposes.” After a remand, the Second Circuit then held in NNFA v. Mathews that FDA could not discharge its burden. The court found that, because the agency failed to show that therapeutic use “far outweighed [the products’] use as dietary supplements,” and because none of the promotional materials cited by the agency were attributable to the manufacturers, the agency could not show that the vitamins were intended to be used as drugs. Following the NNFA cases, the D.C. Circuit held in ASH v. Harris that “consumers must use the

73 According to that document, the intended use of a product “may be determined by looking at the totality of circumstances surrounding the distribution of the article.” FDA, Guidance for Industry and FDA Staff: Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only, 9 (2013).


75 See generally FDA, Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions (2011).

76 NNFA v. FDA, 504 F.2d at 789.

77 NNFA v. Weinberger, 512 F.2d 688, 703 (2d Cir. 1975) (emphasis added).

78 NNFA v. Mathews, 557 F.2d at 336 (emphasis added).
product predominately—and in fact nearly exclusively—with the appropriate intent before the requisite statutory intent can be inferred.” 79

We are aware of exactly one case where this exacting test was effectively met. In 2001, a district court found that sellers of nitrous oxide balloons at a rock concert in Washington, D.C. intended for the gas to be used as a drug despite the government’s inability to introduce any labeling or advertising materials into evidence.80 In that case, “[t]he government argue[d] that the Court should . . . view the totality of the circumstances” to find an intended drug use for the nitrous oxide balloons.81 But the court did not actually endorse the government’s “totality” argument as its own view. Instead, the court followed ASH v. Harris and stated that evidence of “consumer intent” could be relevant if it is “strong enough to justify an inference as to the vendor’s intent.”82 The court then held that, under the “obviously unique” facts of that case, “the sellers did not need to label or advertise their product” because the “environment provided the necessary information between buyer and seller.”83

These cases do not reflect a totality standard, but rather establish that FDA may rely on circumstantial evidence of consumer intent only when its probative value is sufficient to negate any explanation other than the intended use of the product as a drug or device. Under a totality standard, however, FDA would be free to determine where the balance of evidence lies and to ascribe whatever probative value it chooses to circumstantial evidence, or at least could argue that another fact finder could do so. Under such a scheme, facts of even marginal relevance can be considered as part of a larger mix of circumstances, even if the probative force of each fact is relatively weak. That would be a substantial change in the law.84

79 ASH v. Harris, 655 F.2d at 240 (emphasis added).
81 Id. at 118 (emphasis added).
82 Id. at 119 (quoting ASH v. Harris, 655 F.2d at 239).
83 Id. The preamble to the Final Rule also cites United States v. 789 Cases, More or Less, of Latex Surgeons’ Gloves, an Article of Device, 799 F. Supp. 1275, 1285 (D. Puerto Rico 1992), as a purported example of a court finding an intended use based on the circumstances surrounding the product’s sale. Any commentary to that effect in Surgeons’ Gloves is dicta. The manufacturer in that case had “represented that its gloves were to be used as surgeons gloves or as dental examination gloves.” Id. at 1280. Because the manufacturer had “created a market for [its] product to be used as a device,” the district court refused to entertain the manufacturer’s post hoc assertions that “the product has a different—and non-regulated use.” Id. at 1285.
84 FDA claims that it previously “relied on circumstantial evidence of intended use” to target “street drug alternatives” and/or counterfeit drugs that had been deliberately mislabeled. 82 Fed. Reg. at 2208. The examples provided in the preamble to the Final Rule were not accompanied by citation to any judicial decision, and most of the examples appear to be referring to FDA warning letters or similar correspondence. See, e.g., Warning Letter to Global Vision Product (Apr. 3, 2003); Warning Letter to Legal Gear and Affordable Supplements (Mar. 8, 2006); Warning Letter to Kanec USA, Inc. (Oct. 8, 2010). Warning letters and other agency correspondence are, however, merely statements by FDA employees and are not subject to judicial review. See Holistic Candlers & Consumers
Similarly, the preamble to the Final Rule indicates that the totality standard is meant to allow FDA to scrutinize internal company documents to find an intended use, even if those documents have not been published to the marketplace. FDA relies primarily on an in limine ruling from the district court in United States v. Vascular Solutions, Inc., a case in which the government stated that it would rely “on promotional speech . . . alone,” but where the court nevertheless addressed the admissibility of a hypothetical bumper sticker locked in a briefcase and never made public. While touting a pre-trial ruling concerning hypothetical facts, FDA failed to discuss an Eighth Circuit case that dealt with that scenario in real terms—and reached a contrary conclusion. In United States v. Articles of Drug for Veterinary Use, the Eighth Circuit upheld a jury verdict for the defendant and held that the government could not rely on written materials stored in a warehouse as evidence of intended use because the government failed to establish that they “were promotional in nature” or “were ever distributed in relation to the six products seized.”

Further, FDA misunderstands the case law suggesting that the government can consider “any relevant source” in assessing the manufacturer’s intended use. Those cases merely state that any relevant source of claims is potentially relevant to the intended use inquiry. The phrase has its roots in United States v. 3 Cartons . . . “No. 26 Formula GM,” where the manufacturer had attempted to avoid regulation as a drug by omitting and even disclaiming therapeutic uses in the label for its product. The court rejected that argument, finding authority to consider “any source which discloses the intended use.” In particular, the court relied on the “literature” disseminated by the manufacturer, which had “consistently represented these products as efficacious in the treatment, mitigation, and prevention of many ailments including some of the most serious that afflict mankind.”

Ass’n v. FDA, 664 F.3d 940, 941-42 (D.C. Cir. 2012). Those letters are not the law, and they provide no support for FDA’s proposal to expand intended use by adding a new totality standard to 21 C.F.R. §§ 201.128 and 801.4. See, e.g., Sottera, Inc. v. FDA, 627 F.3d 891, 897 (D.C. Cir. 2010) (“FDA’s claimed authority” in a warning letter was irrelevant because it was “never challenged or adjudicated in court.”).

See 82 Fed. Reg. at 2207-08.


United States v. Articles of Drug for Veterinary Use, 50 F.3d 497, 501 (8th Cir. 1995).

See 82 Fed. Reg. at 2206 (“FDA’s longstanding position is that, in determining a product’s intended use, the Agency may look to any relevant source of evidence. This position has solid support in the case law.”).


Id. at 574.

Id. at 573.
Virtually all of the cases cited by FDA follow the same pattern. Thus, in *V.E. Irons, Inc. v. United States*, the First Circuit stated that it could “look at all relevant sources” in response to an argument that the intended use analysis should be “confined to the labels on the drug or the ‘labeling.’”  The court found that the relevant sources were “all of appellants’ literature as well as the oral representations made by [its president] at his lectures or by authorized sales distributors.” At no point did the court consider evidence beyond the manufacturer’s affirmative representations regarding its products.

The Second Circuit’s decision in *Sudden Change* provides still more confirmation that FDA’s totality approach has no basis in the law. In that case, the court coined the phrase that “the intended use of a product may be determined from its label, accompanying labeling, promotional material, advertising and any other relevant source.” In explaining this test, the court made clear that it applies only to certain types of promotional claims:

Regardless of the actual physical effect of a product, it will be deemed a drug for purposes of the Act where the labeling and promotional claims show intended uses that bring it within the drug definition. . . . Thus, Congress has made a judgment that a product is subject to regulation as a drug if certain promotional claims are made for it.

Indeed, every one of the nine cases cited in the *Sudden Change* opinion considered only promotional claims.

---

92 *V.E. Irons, Inc. v. United States*, 244 F.2d 34, 44 (1st Cir. 1957).
93 Id.
94 *Sudden Change*, 409 F.2d at 739.
95 Id. (emphases added). That “any relevant source” is limited to sources of promotional claims like labeling and advertising also is confirmed by the canon of *ejusdem generis*—when general words like “any other relevant source” follow specific words (here, “labeling, promotional material, and advertising”), the general words are said to embrace “only objects similar in nature to those objects enumerated by the preceding specific words.” *Yates v. United States*, 135 S. Ct. 1074, 1086 (S. Ct. 2015) (citations omitted).
96 *United States v. Article of Drug Designed B-Complex Cholinos Capsules*, 362 F.2d 923, 925-26 (3d Cir. 1966) (“radio broadcasts” that included “advertisements . . . presented as commercials” established intended uses); *United States v. Articles of Drug . . . 250 Jars ‘Cal’s Tupelo Blossom U.S. Fancy Pure Honey,’” 344 F.2d 288, 289 (6th Cir. 1965) (“a reading of the booklets and mailing leaflets resulted in the inescapable conclusion that such honey was intended to be used as a drug”); *United States v. Millpax, Inc.* 313 F.2d 152, 154-55 (7th Cir. 1963) (prior customer “testimonials” published in a magazine and an oral recommendation to a potential customer showed that a “cancer cure” was a drug notwithstanding a disclaimer sent by the defendant’s attorney); *Nature Food Ctrs., Inc. v. United States*, 310 F.2d 67, 69-70 (1st Cir. 1962) (“lectures” and “notes” distributed by company representatives “made fulsome claims as to the preventative and curative qualities of [the] various products”); *United States v. Hohensee*, 243 F.2d 367, 370 (3d Cir. 1957) (“oral representations to users and prospective users” were “no less relevant than labeling because “[b]oth show that the products shipped were to be used as drugs”); *Bradley*, 264 F. at 82 (water held to be a drug under the 1906 Act when marketed subject to therapeutic claims); *United States v. 354 Bulk
Later cases, including those cited by FDA, also relied on promotional claims to find an intended use rather than an ad hoc, “totality” approach. For example, the district court decisions in both *Hanson v. United States* and *United States v. Undetermined Quantities of an Article of Drug Labeled as “Exachol,”* incorporated the same language and citations from *Sudden Change,* and also relied on explicit promotional claims to find an intended use.97 Similarly, the district court decisions in *United States v. Lane Labs-USA, Inc.* and *United States v. Kasz Enterprises, Inc.* also relied on explicit claims to find intended drug uses.98

Even as to the specific question of manufacturer knowledge, the Final Rule represents a change in FDA’s own position. The agency itself has previously argued that awareness of an actual use cannot be used to show an intended use, even if there is corroborating evidence.99 In several instances, FDA has argued that the product’s labeling determines its intended uses.100 Codifying a totality of the evidence standard in 21 C.F.R. §§ 201.128 and 801.4 would change that position without addressing FDA’s prior contrary interpretations.

FDA’s citation to *United States v. Storage Spaces Designated Nos. 8 and 49* is particularly inapposite. FDA claims that the Ninth Circuit relied on “the overall circumstances” to find an intended use for drugs that were “innocuously labeled” but actually contained imitation cocaine.101 However, the phrase “overall circumstances” appears only in a

---

97 *Hanson v. United States,* 417 F. Supp. 30, 35 (D. Minn. 1976) (“The promotional materials . . . make similar claims” that “the ingestion of laetrile results in the ‘prevention, control, arrest and minimization of cancerous tissue growths.’”), aff’d, 540 F.2d 947 (8th Cir. 1976) (per curiam); *United States v. Undetermined Quantities of an Article of Drug Labeled as “Exachol,”* 716 F. Supp. 787, 792 (S.D.N.Y. 1989) (“The claims clearly identify a product which is intended to prevent cholesterol deposits and thereby to mitigate the possibility of coronary thrombosis.”).

98 *United States v. Lane Labs-USA, Inc.*, 324 F. Supp. 2d 547, 568 (D.N.J. 2004) (“many of the materials at issue in this action blatantly claimed that the given product was an effective treatment for cancer or HIV/AIDS”); *United States v. Kasz Enters., Inc.*, 855 F.Supp. 534, 540 (D.R.I. 1994) (“The promotional materials accompanying Solutions 109 are replete with claims (testimonials) that hair growth has occurred and hair loss prevented with use of these products.”).

99 *Sigma-Tau,* 288 F.3d at 145.

100 See id. at 146 (“The FDA determined the intended use for [the] generic drugs by relying primarily upon the proposed labeling provided by the companies.”); *Spectrum Pharms., Inc. v. Burwell,* 824 F.3d 1062, 1067 (D.C. Cir. 2016) (“FDA responds that it need look no further than the use indicated in [the abbreviated new drug application] . . . We agree with FDA . . . .”); see also *Ribavirin Petition Response,* supra note 21, at 22 (“Here, the proposed labeling would be the most relevant and compelling, if not exclusive, manifestation of the objective intent of the ANDA applicant legally responsible for that proposed generic ribavirin capsule drug product.”).

101 82 Fed. Reg. at 2208.
footnote rebutting the defendants’ arguments that their products’ labels should be controlling as to the products’ intended uses. In the main text, the court determined that the products were intended for use as drugs based on “leaflets,” a “flyer,” and “catalogs and advertisements,” all of which claimed “that the products could produce stimulation, as cocaine does.”

The Agency’s reliance on *United States v. An Article of Device Toftness Radiation Detector* is also misplaced. The Seventh Circuit had no occasion to evaluate the sufficiency of the evidence of intended use presented at trial, much less the propriety of a “totality of evidence” standard, because the defendants did not challenge the evidence. In fact, they introduced much of the evidence themselves, and argued that it showed that their device “was not intended to be used as the sole means of diagnosing patients” and that their device was “intended only for research.” The court determined that both arguments failed as a matter of law, explaining that an “instrument need not be the only agent in an allegedly curative process to be a device within the definition,” and that “the Act and its regulations do not except instruments involved in research from the definition of ‘device.’”

Finally, FDA cites the D.C. Circuit’s opinion in *ASH v. Harris*, but that case holds that “the crux of FDA jurisdiction over drugs lay in manufacturers’ representations as revelatory of their intent” and that this “understanding has now been accepted as a matter of statutory interpretation.” Far from embracing the totality standard that FDA posited, the D.C. Circuit rejected the argument that the intended use of cigarettes should be inferred from the circumstances surrounding their manufacture and distribution.

**b. The totality standard would introduce significant constitutional concerns.**

As explained in the prior section, the cases interpreting “intended use” under the FDCA do not allow the agency to consider any and all categories of evidence, without limits, to show an intended use. Instead, cases hold that intended uses “must be determined from objective evidence in promoting, distributing, and selling the [drug or] device.” In particular, a manufacturer *must* make an explicit promotional claim before FDA may find a new intended use.

---

102 *United States v. Storage Spaces Designated Nos. 8 and 49*, 777 F.2d 1363, 1366 n.5 (9th Cir. 1985).
103 *Id.* at 1366.
104 *United States v. An Article of Device Toftness Radiation Detector*, 731 F.2d 1253, 1257 (7th Cir. 1984) (emphasis added).
105 *Id.* at 1258.
107 *Id.* at 239-40.
FDA’s totality standard not only departs from existing law, but also raises serious constitutional concerns.

To be sure, the traditional claims-based interpretation of intended use, which predated the development of contemporary commercial speech case law, raises challenging First Amendment questions.\textsuperscript{109} Moreover, a vague standard allowing the prosecution of manufacturers for misbranding violations based merely on inferences of promotional claims drawn from the “totality of circumstances” violates the Due Process clause of the Fifth Amendment by failing to provide regulated parties “fair notice of conduct that is forbidden or required.”\textsuperscript{110} These concerns are heightened when the lack of clarity chills protected speech.\textsuperscript{111}

FDA’s new “totality of the evidence” test all but guarantees significant constitutional harms will result. For instance, the Final Rule exacerbates the already intolerable uncertainty that FDA’s regulations and enforcement actions have created with respect to the boundaries of criminal liability. As the MIWG explained in its 2013 citizen petition, the Due Process Clause of the Fifth Amendment requires that the government regulate with “precision” in this arena and provide fair notice to regulated industry as to the conduct that can (and cannot) lead to potential liability.\textsuperscript{112} As the MIWG also explained, the lack of \textit{a priori} rules clearly defining and limiting the government’s ability to allege an intended use under 21 C.F.R. §§ 201.128 and 801.4 violates those due process principles because the open-ended intended use regulations leave manufacturers unable to evaluate, in advance, the lawfulness of proposed business practices.\textsuperscript{113} Experience has shown that prosecutors (and the private \textit{qui tam} bar) have relied on 21 C.F.R. §§ 201.128 and 801.4 to allege \textit{after the fact} that business practices have misbranded a product because they provide circumstantial evidence of an intended use, even if that use was in no way promoted by the defendant. Codifying a “totality” standard in the intended use regulations will

\textsuperscript{109} In \textit{United States v. Caronia}, the court held that truthful and non-misleading promotional claims are protected by the First Amendment, and invoked the canon of constitutional avoidance to adopt a construction of the FDCA that obviated a collision between FDA’s implementation of the statute and important constitutional restrictions on the agency’s power to regulate manufacturer communications. See 703 F.3d 149, 160, 162 (2d Cir. 2012); see also \textit{Amarin Pharm., Inc. v. FDA}, 119 F. Supp. 3d 196, 225 & n.56 (S.D.N.Y. 2015). FDA currently is engaged in a “comprehensive review” of its regulatory scheme, which has involved a public hearing and, more recently, the agency’s publication of a lengthy memorandum reflecting its perspective on the application of First Amendment principles to its regulatory authorities under the FDCA. See Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products; Public Hearing; Request for Comments, 81 Fed. Reg. 60,299 (Sept. 1, 2016); FDA Memorandum, Public Health Interests and First Amendment Considerations Related to Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products, Docket No. FDA-2016-N-1149 (Jan. 2017).


\textsuperscript{111} \textit{Id.} at 2318 (fair notice principles operate with greater force “when applied to . . . regulations that touch upon ‘sensitive areas of basic First Amendment freedoms’”) (quoting \textit{Baggett v. Bullitt}, 377 U.S. 360, 372 (1964)).

\textsuperscript{112} Citizen Petition, Docket No. FDA-2013-P-1079, at 8 (Sept. 3, 2013).

\textsuperscript{113} \textit{Id.} at 15-19.
only make these problems worse. Under a totality standard, no one will be able to know, in advance, what evidence (or even types of evidence) a prosecutor might consider sufficient to deem an actual use to be an intended use, raising significant Fifth Amendment concerns.

Similarly, and as discussed below, the new “totality” standard would not only risk the restriction of truthful and non-misleading promotional speech, but also chill non-promotional speech that FDA has consistently recognized as beneficial to the public health.

c. The totality standard would negatively impact the public health by chilling valuable scientific speech.

Under a “totality of the evidence” standard, everything may be considered to establish a product’s intended use. This standard would allow FDA to rely even on non-promotional scientific exchange as evidence of intended use. Such evidence could include speech with significant public health benefits, including a firm’s distribution of reprints, clinical practice guidelines, or reference texts regarding unapproved uses of approved/cleared medical products; its responses to unsolicited requests for information about such uses; its presentation of truthful and non-misleading scientific information about unapproved uses at medical or scientific conferences; and its discussions of such uses with third-party payers. Although FDA has issued non-binding guidance documents or draft guidance documents concerning some of these activities, any such statements appear to be trumped by the binding totality standard codified at 21 C.F.R. §§ 201.128 and 801.4.

The chilling effect of such a standard is difficult to overstate. For example, if a company engages in scientific exchange about off-label use, forecasts on- and off-label sales, and scales production to meet the combined demand, a prosecutor could decide that this evidence reflects an off-label intended use. Combined with the substantial penalties and resulting pressure companies face to settle criminal misbranding cases, the new intended use rule exposes manufacturers to a significant risk of liability for conduct that is entirely lawful and beneficial to the public health. The result of the Final Rule is therefore that speech regarding valuable scientific and medical information will be chilled, negatively impacting the public health.

IV. Conclusion

For the foregoing reasons, reconsideration should be granted, the Final Rule published on January 9, 2017 should be indefinitely stayed, and FDA staff should promulgate final intended use definitions consistent with the definitions set out in the September 2015 notice of proposed rulemaking.
Respectfully submitted,

Paul E. Kalb  
Coleen Klasemeier  
Joseph R. Guerra  
Sean C. Griffin  
SIDLEY AUSTIN LLP  
1501 K Street NW  
Washington, DC 20001  
(202) 736-8000

Kellie B. Combs  
Douglas H. Hallward-Driemeier  
ROPES & GRAY LLP  
2099 Pennsylvania Avenue NW  
Washington, DC 20006  
(202) 508-4600

James C. Stansel  
PHARMACEUTICAL RESEARCH  
AND MANUFACTURERS OF AMERICA  
950 F Street NW, Suite 300  
Washington, DC 20004  
(202) 835-3400

Joan McPhee  
ROPES & GRAY LLP  
1211 Avenue of the Americas  
New York, NY 10036  
(212) 596-9000

John Murphy  
BIOTECHNOLOGY INNOVATION  
ORGANIZATION  
1201 Maryland Avenue, SW Suite 900  
Washington, DC 20024  
(202) 962-9200

Justin Florence  
ROPES & GRAY LLP  
800 Boylston Street  
Boston, MA 02199  
(617) 951-7000